Skip to main content

Table 2 Subgroups analysis of the primary outcomes that showed in-between-study heterogeneity

From: Autologous bone-marrow mononuclear stem cell therapy in patients with stroke: a meta-analysis of comparative studies

Item Parameter Studies Patients SMD P I2 % (model)
Mode of administration
 NIHSS (3 months) IA 3 107 − 0.64 [− 1.03, − 0.25] 0.001a 0 (F)
IV 2 150 1.35 [0.97, 1.72] < 0.001a 0 (F)
 BI (3 months) IA 3 79 − 0.33 [− 0.90, 0.24] 0.26 34 (F)
IV 2 70 2.97 [2.23, 3.71] < 0.001a 0 (F)
 BI (6 months) IA 4 119 1.37 [− 0.61, 3.34] 0.18 95 (R)
IV 2 150 1.01 [− 0.87, 2.88] 0.29 90 (R)
IC 1 100 1.34 [0.89, 1.78] NA NA
Cell type
 NIHSS (3 months) BM-MNCs 3 188 0.57 [0.26, 0.89] < 0.001a 95 (R)
MSC 2 69 − 0.07 [− 0.61, 0.47] 0.79 82 (R)
 BI (3 months) BM-MNCs 3 80 0.56 [− 1.63, 2.76] 0.61 94 (R)
MSC 2 69 1.66 [− 1.91, 5.23] 0.36 96 (R)
 BI (6 months) BM-MNCs 5 300 1.24 [0.01, 2.48] 0.05 95 (R)
MSC 2 69 1.08 [− 0.69, 2.84] 0.23 87 (R)
  1. BI the Barthel Index, BM-MNCs bone marrow mononuclear cells, F a fixed-effects model, IA intra-arterial, IC intracranial (perilesional), IV intravenous, MSCs mesenchymal stem cells, NIHSS the National Institutes of Health Stroke Scale, R random-effects model, SMD standardized mean difference
  2. aIndicates statistically significant differences